amiratx.com
  • Home
  • AMI463
  • Pipeline
  • Partners
  • Resources
  • Contact
Select Page

Amira Therapeutics’ Lead Compound AMI463 Demonstrates 60% Tumor Reduction in Preclinical Oral Study

by Sergi | Dec 15, 2025 | Press Releases

Amira Therapeutics’ Lead Compound AMI463 Demonstrates 60% Tumor Reduction in Preclinical Oral Study AMI463 has been tested in a murine model showing a tumor reduction of 60% compared with the control group. Amira is currently preparing a meeting with the AEMPS to...

Recent Posts

  • Amira Therapeutics’ Lead Compound AMI463 Demonstrates 60% Tumor Reduction in Preclinical Oral Study
  • Amira Therapeutics Receives Orphan Drug Designation for AMI463 in Soft Tissue Sarcoma in the United States
  • Cell biology of protein–lipid conjugation
  • Targeting the Hedgehog Pathway in Rhabdomyosarcoma
  • RCAN1-mediated calcineurin inhibition as a target for cancer therapy

Recent Comments

No comments to show.

Privacy Policy

Legal Notice

Cookie Policy

Related Publications

  • 2025
  • 2024
  • 2023
  • 2022
Ready to help children beat cancer
  • X
  • RSS
© 2023 Amira Therapeutics, SL